The BioWorld Artificial Intelligence price-weighted index, which includes biopharmaceutical companies, medical devices and health care services companies, has climbed in value and is currently up almost 37% year-to-date.

The volume of clinical data reported throughout the summer has continued to fall, with only 267 items collected in August, a drop of 10% from July and the lowest amount within the last five months.

As biopharma deal values continue to rise above recent years, a growing percentage of the funds are coming through partnerships with companies headquartered in Asia and nearby countries. The $48.5 billion reported so far in 2020, for deals in which at least one party is based in either Asia, Australia or New Zealand, represents 37% of the global deal value.

In a relatively light news flow for the group last month, the gainers and decliners in the BioWorld Neurological Diseases index canceled themselves out during August, with the result that the price-weighted index closed relatively flat and, despite briefly moving into positive territory in July, its value is down 4% for the year.